RU2020124172A - Слитые серпиновые полипептиды и способы их применения - Google Patents
Слитые серпиновые полипептиды и способы их применения Download PDFInfo
- Publication number
- RU2020124172A RU2020124172A RU2020124172A RU2020124172A RU2020124172A RU 2020124172 A RU2020124172 A RU 2020124172A RU 2020124172 A RU2020124172 A RU 2020124172A RU 2020124172 A RU2020124172 A RU 2020124172A RU 2020124172 A RU2020124172 A RU 2020124172A
- Authority
- RU
- Russia
- Prior art keywords
- polypeptide
- fusion protein
- human
- isolated fusion
- aat
- Prior art date
Links
- 102000008847 Serpin Human genes 0.000 title 1
- 108050000761 Serpin Proteins 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108020001507 fusion proteins Proteins 0.000 claims 16
- 102000037865 fusion proteins Human genes 0.000 claims 16
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 9
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 9
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- 102000002149 Elafin Human genes 0.000 claims 5
- 108010015972 Elafin Proteins 0.000 claims 5
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 5
- 101001048718 Homo sapiens Elafin Proteins 0.000 claims 3
- 102000051409 human PI3 Human genes 0.000 claims 3
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 102220516587 Kynurenine-oxoglutarate transaminase 1_T256E_mutation Human genes 0.000 claims 1
- 102000051631 human SERPINA1 Human genes 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 102220053319 rs139287714 Human genes 0.000 claims 1
- 102220325920 rs746060028 Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
Claims (15)
1. Выделенный слитый белок, содержащий по меньшей мере один полипептид альфа-1-антитрипсина (AAT), полипептид элафина, Fc-полипептид иммуноглобулина, такой что по меньшей мере два из полипептида ААТ, полипептида элафина и Fc-полипептида иммуноглобулина функционально связаны посредством шарнирной области, линкерной области или шарнирной области и линкерной области.
2. Выделенный слитый белок по п. 1, где полипептид ААТ представляет собой человеческий полипептид альфа-1-антитрипсина (AAT) или получен из человеческого полипептида ААТ.
3. Выделенный слитый белок по п. 2, где полипептид ААТ содержит аминокислотную последовательность SEQ ID NO: 2.
4. Выделенный слитый белок по п. 2, где полипептид ААТ содержит петлю реакционного сайта AAT, содержащего аминокислотную последовательность SEQ ID NO: 1 или петлю реакционного сайта AAT, содержащего аминокислотную последовательность SEQ ID NO: 32 или 33.
5. Выделенный слитый белок по п. 2, где Fc-полипептид иммуноглобулина представляет собой человеческий Fc-полипептид.
6. Выделенный слитый белок по п. 5, где человеческий Fc-полипептид представляет собой полипептид человеческого IgM или Fc-полипептид человеческого IgG.
7. Выделенный слитый белок по п. 6, где Fc-полипептид человеческого IgG представляет собой Fc-полипептид человеческого IgG1, Fc-полипептид человеческого IgG2, Fc-полипептид человеческого IgG3 или Fc-полипептид человеческого IgG4.
8. Выделенный слитый белок по п. 7, где Fc-полипептида иммуноглобулина содержит аминокислотную последовательность, выбранную из группы, состоящей из SEQ ID NO: 3, 4, 5, 6 и 7.
9. Выделенный слитый белок по п. 1, где шарнирная область, линкерная область или шарнирная область и линкерная область содержат пептидную последовательность.
10. Выделенный слитый белок по п. 1, где слитый белок содержит аминокислотную последовательность SEQ ID NO: 29.
11. Выделенный слитый белок по п. 1, где Fc-полипептид иммкноглобулина модифицирован, чтобы повысить связывание с FcRn.
12. Выделенный слитый белок по п. 11, где Fc-полипептид иммуноглобулина содержит по меньшей мере одну из следующих мутаций: Met252Tyr, Ser254Thr, Thr256Glu, Met428Leu или Asn434Ser.
13. Выделенный слитый белок по п. 1, где полипептид элафина представляет собой полипептид человеческого элафина.
14. Выделенный слитый белок по п. 13, где полипептид человеческого элафина представляет собой полноразмерный полипептид элафина или получен из полипептида человеческого элафина.
15. Выделенный слитый белок по п. 1, где полипептид элафина содержит аминокислотную последовательность, выбранную из группы, состоящей из SEQ ID NO: 11, 12 и 13.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161502055P | 2011-06-28 | 2011-06-28 | |
US61/502,055 | 2011-06-28 | ||
US201161570394P | 2011-12-14 | 2011-12-14 | |
US61/570,394 | 2011-12-14 | ||
US201161577204P | 2011-12-19 | 2011-12-19 | |
US61/577,204 | 2011-12-19 | ||
US201261638168P | 2012-04-25 | 2012-04-25 | |
US61/638,168 | 2012-04-25 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019121798A Division RU2728861C1 (ru) | 2011-06-28 | 2019-07-11 | Слитые серпиновые полипептиды и способы их применения |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2020124172A true RU2020124172A (ru) | 2022-01-21 |
Family
ID=47424806
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014102583A RU2642310C2 (ru) | 2011-06-28 | 2012-06-28 | Слитые серпиновые полипептиды и способы их применения |
RU2017145308A RU2698655C2 (ru) | 2011-06-28 | 2012-06-28 | Слитые серпиновые полипептиды и способы их применения |
RU2019121797A RU2727452C1 (ru) | 2011-06-28 | 2012-06-28 | Слитые серпиновые полипептиды и способы их применения |
RU2019121798A RU2728861C1 (ru) | 2011-06-28 | 2019-07-11 | Слитые серпиновые полипептиды и способы их применения |
RU2020124172A RU2020124172A (ru) | 2011-06-28 | 2020-07-21 | Слитые серпиновые полипептиды и способы их применения |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014102583A RU2642310C2 (ru) | 2011-06-28 | 2012-06-28 | Слитые серпиновые полипептиды и способы их применения |
RU2017145308A RU2698655C2 (ru) | 2011-06-28 | 2012-06-28 | Слитые серпиновые полипептиды и способы их применения |
RU2019121797A RU2727452C1 (ru) | 2011-06-28 | 2012-06-28 | Слитые серпиновые полипептиды и способы их применения |
RU2019121798A RU2728861C1 (ru) | 2011-06-28 | 2019-07-11 | Слитые серпиновые полипептиды и способы их применения |
Country Status (27)
Country | Link |
---|---|
US (7) | US8980266B2 (ru) |
EP (2) | EP2726092B1 (ru) |
JP (4) | JP2014523900A (ru) |
KR (5) | KR102084944B1 (ru) |
CN (3) | CN103917563A (ru) |
AU (4) | AU2012275287B2 (ru) |
BR (1) | BR112013033799A2 (ru) |
CA (2) | CA3132298A1 (ru) |
CY (1) | CY1122195T1 (ru) |
DK (1) | DK2726092T3 (ru) |
ES (1) | ES2746052T3 (ru) |
HR (1) | HRP20191652T1 (ru) |
HU (1) | HUE046156T2 (ru) |
IL (3) | IL312872A (ru) |
IN (1) | IN2013MN02441A (ru) |
LT (1) | LT2726092T (ru) |
ME (1) | ME03473B (ru) |
MX (1) | MX356517B (ru) |
NZ (1) | NZ744257A (ru) |
PL (1) | PL2726092T3 (ru) |
PT (1) | PT2726092T (ru) |
RS (1) | RS59368B1 (ru) |
RU (5) | RU2642310C2 (ru) |
SG (2) | SG10201601621PA (ru) |
SI (1) | SI2726092T1 (ru) |
UA (1) | UA124083C2 (ru) |
WO (1) | WO2013003641A2 (ru) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9938353B2 (en) | 2011-06-24 | 2018-04-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
US10400029B2 (en) * | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
CN103917563A (zh) * | 2011-06-28 | 2014-07-09 | 英伊布里克斯有限责任公司 | 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法 |
JP2014528913A (ja) * | 2011-06-28 | 2014-10-30 | インヒブルクス リミティド ライアビリティ カンパニー | Wapドメイン融合ポリペプチド及びその使用方法 |
CA2896951A1 (en) * | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
WO2013156054A1 (en) * | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
KR101509020B1 (ko) * | 2013-05-22 | 2015-04-14 | (주)입디 | 알파 1 안티트립신 융합 분자에 대한 조성물, 방법 및 용도 |
US20170190762A1 (en) | 2014-06-11 | 2017-07-06 | Beth Israel Deaconess Medical Center, Inc. | Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases |
TW201613981A (en) | 2014-07-23 | 2016-04-16 | Inova Diagnostics Inc | Compositions and methods for the diagnosis of rheumatoid arthritis |
IL308589A (en) * | 2014-10-27 | 2024-01-01 | Inhibrx Inc | Serpin-fused polypeptides and methods of using them |
US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
US11422719B2 (en) * | 2016-09-15 | 2022-08-23 | Pure Storage, Inc. | Distributed file deletion and truncation |
US12031144B2 (en) * | 2017-03-29 | 2024-07-09 | Cornell University | Oxidation-resistant AAT gene therapy |
JP7291119B2 (ja) * | 2017-07-27 | 2023-06-14 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | プラスミノーゲン活性化因子阻害剤-1(pai-1)阻害剤および使用方法 |
US11857610B2 (en) | 2017-12-01 | 2024-01-02 | Csl Behring Llc | Methods for reducing risk of onset of acute graft versus host disease after hematopoietic cell transplantation |
JP2022509517A (ja) * | 2018-10-29 | 2022-01-20 | スピン セラピューティクス, エルエルシー | アルファ-1-アンチトリプシン欠乏症のための組成物及び方法 |
WO2021022212A2 (en) * | 2019-08-01 | 2021-02-04 | Serplus Technology Llc | Oxidation-resistant serpins |
CN110964094B (zh) * | 2019-12-20 | 2021-11-02 | 华中科技大学 | 人源白细胞蛋白酶抑制因子及其重组制备与应用 |
CN112341538A (zh) * | 2020-10-27 | 2021-02-09 | 苏州复融生物技术有限公司 | 一种Fc单体多肽及其应用 |
CA3206022A1 (en) * | 2021-01-26 | 2022-08-04 | Traian Sulea | Ace2-receptor ectodomain fusion molecules and uses thereof |
GB202102258D0 (en) | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
WO2023122120A1 (en) * | 2021-12-22 | 2023-06-29 | The Regents Of The University Of California | Compositionsand methods for wound healing |
TW202409072A (zh) | 2022-05-16 | 2024-03-01 | 美商英伊布里克斯公司 | 用於治療個體的α-1抗胰蛋白酶(AAT)缺乏症之方法的重組絲胺酸蛋白酶抑制劑(serpin)-Fc融合蛋白之有效劑量 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
DE69229482T2 (de) | 1991-04-25 | 1999-11-18 | Chugai Seiyaku K.K., Tokio/Tokyo | Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor |
US5734014A (en) | 1992-08-11 | 1998-03-31 | Tsumura & Co. | Elafin derivative |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
TW575567B (en) * | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1161532A1 (en) * | 1999-03-01 | 2001-12-12 | Human Genome Sciences, Inc. | Human serpin proteins |
US6849605B1 (en) * | 1999-03-05 | 2005-02-01 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of viral infections |
CA2373721C (en) | 1999-07-02 | 2013-10-15 | Genentech, Inc. | Compounds that bind her2 |
AU2050501A (en) * | 1999-12-01 | 2001-06-12 | Human Genome Sciences, Inc. | Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies |
EP1278544A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
FR2814957B1 (fr) | 2000-10-06 | 2002-12-20 | Aventis Pasteur | Composition vaccinale et procede de stabilisation |
WO2002038160A1 (en) * | 2000-11-08 | 2002-05-16 | Prometic Biosciences Inc. | Method for the treatment of inflammation |
UA81897C2 (ru) | 2000-12-07 | 2008-02-25 | Эли Лилли Энд Компани | Гетерологический пептидилированный глюкагон-1-подобный белок и его применение для изготовления лекарственного средства для лечения пациентов, страдающих ожирением и/или инсулиннезависимым диабетом |
EP1355919B1 (en) * | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US7247704B2 (en) | 2000-12-18 | 2007-07-24 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
AU2002241661B2 (en) * | 2000-12-18 | 2007-05-31 | Arriva Pharmaceuticals, Inc | Multifunctional protease inhibitors and their use in treatment of disease |
CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
US6797493B2 (en) | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1415664A1 (en) * | 2002-10-30 | 2004-05-06 | Switch Biotech Aktiengesellschaft | Use of alpha 1-antichymotrypsin in combination with alpha-1-antitrypsin for treating/preventing diabetes associated or poorly healing arterial wounds |
US7427595B1 (en) | 2002-12-12 | 2008-09-23 | Cornell Research Foundation, Inc. | Use of proepithelin to promote wound repair and reduce inflammation |
DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
MXPA05013564A (es) | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion. |
EP3192872A1 (en) | 2003-08-26 | 2017-07-19 | The Regents of the University of Colorado, a body corporate | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
EP1682584B1 (en) * | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
WO2005086915A2 (en) * | 2004-03-09 | 2005-09-22 | Arriva Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor |
RU2368622C2 (ru) | 2004-04-13 | 2009-09-27 | Ф.Хоффманн-Ля Рош Аг | Антитела к р-селектину |
WO2005113606A2 (en) | 2004-05-13 | 2005-12-01 | Eli Lilly And Company | Fgf-21 fusion proteins |
AP2007003869A0 (en) | 2004-08-03 | 2007-02-28 | Transtech Pharma Inc | Rage fusion proteins and methods of use |
MX2007001638A (es) | 2004-08-11 | 2009-02-12 | Trubion Pharmaceuticals Inc | Proteinas de fusion del dominio de unión. |
US7399746B2 (en) | 2004-10-06 | 2008-07-15 | Mcgill University | Agents for wound healing |
CN102746404B (zh) | 2004-11-12 | 2016-01-20 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1868650B1 (en) * | 2005-04-15 | 2018-10-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
US8163881B2 (en) * | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
WO2006129849A1 (ja) | 2005-06-03 | 2006-12-07 | Mochida Pharmaceutical Co., Ltd. | 抗cd14抗体融合蛋白質 |
ES2336832T3 (es) | 2005-07-22 | 2010-04-16 | Five Prime Therapeutics, Inc. | Composiciones y procedimientos para tratar enfermedades con proteinas de fusion de fgfr. |
US7713521B2 (en) | 2005-08-12 | 2010-05-11 | Schering Corporation | MCP1 fusions |
EP3811965A1 (en) * | 2005-11-23 | 2021-04-28 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
EP2012819A2 (en) | 2006-03-30 | 2009-01-14 | The Research Foundation Of the City university of New York | Stimulation of neuron regeneration by secretory leukocyte protease inhibitor |
GB0614780D0 (en) * | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
CN101541825B (zh) | 2006-08-28 | 2013-08-14 | 阿雷斯贸易股份有限公司 | Fc融合蛋白的纯化方法 |
US20110020269A1 (en) | 2007-05-08 | 2011-01-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modifying t cell immune responses and inflammation |
US7867491B2 (en) * | 2007-05-30 | 2011-01-11 | Genexine Co., Ltd. | Immunoglobulin fusion proteins |
CA2688434A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
US8598315B2 (en) * | 2007-10-02 | 2013-12-03 | Research Foundation Of City University Of New York | Protein transduction domains derived from secretory leukocyte protease inhibitor |
AR064713A1 (es) | 2007-12-28 | 2009-04-22 | Consejo Nac Invest Cient Tec | Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos |
WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
CA2731546C (en) * | 2008-07-23 | 2013-11-19 | Hanmi Holdings Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
BRPI0916904A2 (pt) | 2008-08-04 | 2016-10-11 | Fiveprime Therapeutics Inc | polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos |
RU2744176C2 (ru) | 2008-12-19 | 2021-03-03 | Макродженикс, Инк. | Ковалентные диантитела и их применение |
EP2417163B1 (en) | 2009-04-10 | 2019-02-27 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
JP5727459B2 (ja) | 2009-04-22 | 2015-06-03 | アルテオゼン, インクAlteogen, Inc | 体内持続性を維持することにより体内半減期が増加したタンパク質またはペプチド融合体 |
SE533763C2 (sv) | 2009-05-04 | 2010-12-28 | Lars Hammar | Upphängningsanordning |
BR112012000830B8 (pt) | 2009-07-08 | 2022-11-22 | Univ Missouri | Óleo produzido por uma população de sementes de soja e método de produção de uma planta de soja |
ES2600631T3 (es) | 2009-11-13 | 2017-02-10 | Five Prime Therapeutics, Inc. | Uso de proteínas del dominio extracelular de FGFR1 para tratar cánceres caracterizados por mutaciones activadoras dependientes de ligando en FGFR2 |
GB201003559D0 (en) | 2010-03-03 | 2010-04-21 | Proteo Biotech Ag | Novel use of elafin |
EP2588140A4 (en) | 2010-06-30 | 2015-07-15 | Univ Maryland | DENTAL COMPOUNDS WITH NANOPARTICLES OF AMORPHIC CALCIUM PHOSPHATE |
KR101900280B1 (ko) | 2010-12-23 | 2018-11-08 | 얀센 바이오테크 인코포레이티드 | 활성 프로테아제-저항성 항체 Fc 돌연변이체 |
RU2607014C2 (ru) | 2011-03-29 | 2017-01-10 | Рош Гликарт Аг | Fc варианты антитела |
EP2537864B1 (en) | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
US9938353B2 (en) * | 2011-06-24 | 2018-04-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
JP2014528913A (ja) | 2011-06-28 | 2014-10-30 | インヒブルクス リミティド ライアビリティ カンパニー | Wapドメイン融合ポリペプチド及びその使用方法 |
CN103917563A (zh) | 2011-06-28 | 2014-07-09 | 英伊布里克斯有限责任公司 | 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法 |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
AU2012279205B2 (en) * | 2011-07-01 | 2017-08-31 | Biogen Ma Inc. | Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use |
CA2896951A1 (en) | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
US20140051834A1 (en) | 2012-06-21 | 2014-02-20 | Hoffmann-La Roche, Inc. | Incretin Receptor Ligand Polypeptide Fc-Region Fusion Polypeptides And Conjugates With Altered Fc-Effector Function |
MX2014014804A (es) | 2012-06-27 | 2015-02-12 | Hoffmann La Roche | Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo. |
JP6307077B2 (ja) | 2012-08-02 | 2018-04-04 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 不活性免疫グロブリンFc領域とのFc融合体としての可溶性FcRを生産するための方法およびその使用 |
EP2929045B1 (en) | 2012-12-05 | 2020-12-02 | SOLA Biosciences LLC | Protein expression enhancing polypeptides |
CN203917563U (zh) | 2014-03-27 | 2014-11-05 | 陈广煌 | 一种切角模具 |
US20170190762A1 (en) * | 2014-06-11 | 2017-07-06 | Beth Israel Deaconess Medical Center, Inc. | Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases |
-
2012
- 2012-06-28 CN CN201280041956.5A patent/CN103917563A/zh active Pending
- 2012-06-28 LT LTEP12804863.4T patent/LT2726092T/lt unknown
- 2012-06-28 CA CA3132298A patent/CA3132298A1/en active Pending
- 2012-06-28 HU HUE12804863A patent/HUE046156T2/hu unknown
- 2012-06-28 CN CN201910871347.6A patent/CN110551223A/zh active Pending
- 2012-06-28 WO PCT/US2012/044730 patent/WO2013003641A2/en active Application Filing
- 2012-06-28 RU RU2014102583A patent/RU2642310C2/ru active
- 2012-06-28 IL IL312872A patent/IL312872A/en unknown
- 2012-06-28 IN IN2441MUN2013 patent/IN2013MN02441A/en unknown
- 2012-06-28 KR KR1020147002346A patent/KR102084944B1/ko active IP Right Grant
- 2012-06-28 RU RU2017145308A patent/RU2698655C2/ru active
- 2012-06-28 US US13/536,976 patent/US8980266B2/en active Active
- 2012-06-28 PT PT128048634T patent/PT2726092T/pt unknown
- 2012-06-28 KR KR1020237024532A patent/KR20230114318A/ko not_active Application Discontinuation
- 2012-06-28 PL PL12804863T patent/PL2726092T3/pl unknown
- 2012-06-28 MX MX2013015323A patent/MX356517B/es active IP Right Grant
- 2012-06-28 RU RU2019121797A patent/RU2727452C1/ru active
- 2012-06-28 SG SG10201601621PA patent/SG10201601621PA/en unknown
- 2012-06-28 DK DK12804863.4T patent/DK2726092T3/da active
- 2012-06-28 ES ES12804863T patent/ES2746052T3/es active Active
- 2012-06-28 ME MEP-2019-253A patent/ME03473B/me unknown
- 2012-06-28 KR KR1020217043197A patent/KR20220003656A/ko not_active Application Discontinuation
- 2012-06-28 CA CA2839619A patent/CA2839619C/en active Active
- 2012-06-28 NZ NZ744257A patent/NZ744257A/en unknown
- 2012-06-28 SI SI201231670T patent/SI2726092T1/sl unknown
- 2012-06-28 AU AU2012275287A patent/AU2012275287B2/en active Active
- 2012-06-28 JP JP2014519049A patent/JP2014523900A/ja active Pending
- 2012-06-28 BR BR112013033799A patent/BR112013033799A2/pt not_active Application Discontinuation
- 2012-06-28 EP EP12804863.4A patent/EP2726092B1/en active Active
- 2012-06-28 KR KR1020217007901A patent/KR20210032558A/ko not_active Application Discontinuation
- 2012-06-28 SG SG10201811256QA patent/SG10201811256QA/en unknown
- 2012-06-28 KR KR1020207005907A patent/KR102231139B1/ko active IP Right Grant
- 2012-06-28 RS RSP20191200 patent/RS59368B1/sr unknown
- 2012-06-28 UA UAA201400709A patent/UA124083C2/uk unknown
- 2012-06-28 CN CN201910132137.5A patent/CN110066340B/zh active Active
- 2012-06-28 EP EP19181040.7A patent/EP3569243A1/en active Pending
-
2013
- 2013-08-19 US US13/969,959 patent/US9920109B2/en active Active
- 2013-12-26 IL IL230209A patent/IL230209B/en active IP Right Grant
-
2015
- 2015-02-06 US US14/616,363 patent/US10730929B2/en active Active
-
2017
- 2017-07-07 JP JP2017134043A patent/JP6674604B2/ja active Active
- 2017-12-21 AU AU2017279724A patent/AU2017279724B2/en active Active
-
2018
- 2018-01-19 US US15/875,010 patent/US10723785B2/en active Active
-
2019
- 2019-04-24 US US16/393,619 patent/US20200102371A1/en not_active Abandoned
- 2019-04-24 AU AU2019202904A patent/AU2019202904B2/en active Active
- 2019-07-11 RU RU2019121798A patent/RU2728861C1/ru active
- 2019-09-13 HR HRP20191652 patent/HRP20191652T1/hr unknown
- 2019-09-18 CY CY20191100993T patent/CY1122195T1/el unknown
-
2020
- 2020-02-06 JP JP2020018783A patent/JP2020078325A/ja active Pending
- 2020-06-22 US US16/908,271 patent/US11827691B2/en active Active
- 2020-07-21 RU RU2020124172A patent/RU2020124172A/ru unknown
- 2020-08-05 IL IL276534A patent/IL276534A/en unknown
- 2020-10-08 US US17/066,410 patent/US11965017B2/en active Active
-
2021
- 2021-04-07 AU AU2021202131A patent/AU2021202131B2/en active Active
-
2022
- 2022-04-21 JP JP2022069976A patent/JP2022109968A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2020124172A (ru) | Слитые серпиновые полипептиды и способы их применения | |
KR102482710B1 (ko) | 항-pd-1 항체, 이의 생산 방법 및 사용 방법 | |
CN107001468B (zh) | Cd3结合结构域 | |
AU2009204501B2 (en) | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects | |
JP5992340B2 (ja) | 抗cd28ヒト化抗体 | |
ES2292682T3 (es) | Purificacion de anticuerpos mediante cromatografia de intercambio ionico. | |
HRP20180937T1 (hr) | Poboljšavanje transporta terapijskih molekula kroz krvno-moždanu barijeru | |
RU2016139006A (ru) | Мультимерные fc-белки | |
RU2009148020A (ru) | ОПТИМИЗИРОВАННЫЙ СЛИТЫЙ БЕЛОК TACI-Fc | |
JP2016508153A5 (ru) | ||
JP2022119917A (ja) | 抗pd1および抗ctla4抗体 | |
WO2017115773A1 (ja) | Fc領域含有ポリペプチドの精製を効率化するための方法 | |
AU2010260476A1 (en) | Methods of purifying small modular immunopharmaceutical proteins | |
JP2010227116A5 (ru) | ||
MX2009012319A (es) | Polipeptidos que se unen a receptores fc con funciones efectoras modificadas. | |
RU2014102585A (ru) | Слитые полипептиды, содержащие домен wap, и способы их применения | |
JP2019502694A (ja) | 二特異性抗体基幹 | |
KR20190065375A (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
WO2015108967A2 (en) | Rsv-specific antibodies and functional parts thereof | |
EP3850010A1 (en) | Improved anti-flt3 antigen binding proteins | |
Traxlmayr et al. | Integrin binding human antibody constant domains—probing the C-terminal structural loops for grafting the RGD motif | |
JP2019511457A5 (ru) | ||
Lee et al. | The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein | |
Capela et al. | Monoclonal antibodies—addressing the challenges on the manufacturing processing of an advanced class of therapeutic agents | |
AU2019374190B2 (en) | Anti-TNFα/anti IL-17A natural antibody structure-like heterodimer form of bispecific antibody and preparation method therefor |